Clinical Trial Update: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ARGX-110 with azacytidine in newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• ARGX-110
• azacytidine (azacitidine)

Snippet

Sponsor: OncoVerity, Inc. | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED